Selectin

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Selectin

Quick Facts

Property Description
Active Ingredient Pravastatin (Sodium)
Form Oral Tablet
Pharmacological Class Statin (HMG-CoA Reductase Inhibitor)
General Purpose Lipid-lowering agent
Origin Semi-synthetic

What is Selectin? Defining the Active Entity

The medicine Selectin is a prescription-only medication classified as a lipid-lowering agent whose identity is based on its active ingredient, Pravastatin (INN). As a single-ingredient product, Selectin belongs to the high-level pharmacological family of statins, which are clinically recognized for their role in controlling cholesterol and blood lipid levels.

Its formulation is a solid, oral tablet intended for oral administration. The Pravastatin component is a semi-synthetic compound derived through fermentation, and it possesses a key hydrophilic (water-soluble) characteristic. This property is pharmacologically important because it directs the drug's activity primarily to the liver, the central organ responsible for cholesterol biosynthesis, minimizing its systemic impact.


Pharmacological Classification and Purpose

Selectin belongs to the specific pharmacological class known as HMG-CoA reductase inhibitors, a designation that describes its core function in lipid regulation. This class of medication works by inhibiting the key enzyme that controls the rate-limiting step of cholesterol production within the body.

The overall general purpose of Selectin is to provide sustained, pharmacological control over the primary factors contributing to elevated blood lipids and cholesterol. For instance, it is typically prescribed to manage hyperlipidemia in adult patients. By significantly reducing the internal manufacturing of cholesterol by the liver, the medicine helps manage hyperlipidemia and other conditions involving abnormal lipid levels. Clinical data indicates that this drug class reduces levels of harmful Low-Density Lipoprotein (LDL) cholesterol in the bloodstream. This role underscores the drug's utility in promoting long-term cardiovascular health and mitigating the risk associated with uncontrolled lipids.

Regulatory References

  1. Pravastatin: MedlinePlus Drug Information

What side effects are possible with Selectin?

Possible Side Effects and Safety Information

The medicine Selectin (Pravastatin) possesses an official safety profile structured by system-organ classes, frequency of occurrence, and specific restrictions. Regulatory documents classify the drug’s potential for adverse effects, with the most significant safety concerns relating to the musculoskeletal system and liver function.


Officially Documented Adverse Reactions

Adverse reactions are grouped according to the physiological system affected, consistent with regulatory classification standards:

  • Musculoskeletal and Connective Tissue Disorders: Includes common musculoskeletal pain, as well as serious reactions such as Myopathy and Rhabdomyolysis (a potentially life-threatening muscle condition). Reports of Immune-Mediated Necrotizing Myopathy (IMNM) are also documented.
  • Gastrointestinal Disorders: Commonly reported effects include Nausea, Vomiting, and Diarrhea.
  • Hepatobiliary Disorders: Serious safety concerns include the risk of Fatal and Non-fatal Hepatic Failure and elevated liver enzyme levels (serum transaminases).
  • Nervous System Disorders: Common effects include Headache and Dizziness.

Safety Restrictions and Population Considerations

The use of Selectin is officially contraindicated (must not be used) in patients with Active Liver Disease or unexplained, persistent elevations of serum transaminases. It is also restricted during Pregnancy and Lactation due to the potential for fetal or infant harm, as stated in regulatory safety information. Furthermore, official labeling identifies advanced age (65 years and older) and renal impairment as predisposing factors that may increase a patient's risk of developing serious skeletal muscle adverse reactions.

Overdose and Emergency Response

The official regulatory profile for Selectin (Pravastatin) overdose centers on the risk of severe, life-threatening musculoskeletal damage and the mandated emergency response. Overexposure may present as myopathy, characterized by unexplained muscle pain, tenderness, or weakness, particularly if accompanied by fever or malaise. The most critical documented severe outcome is rhabdomyolysis (severe muscle breakdown), which has been reported to lead to acute renal failure (kidney damage). This physiological risk is also noted to affect the hepatic system, potentially resulting in serious hepatic injury requiring drug discontinuation. Laboratory findings requiring action include markedly elevated Creatine Phosphokinase (CPK) levels. No specific antidote is known for Pravastatin overdose. Treatment is officially defined as symptomatic and supportive. Regulatory guidance mandates that patients seek immediate medical attention for suspected overdose. Urgent medical help is required if severe systemic signs occur, such as collapse, having a seizure, trouble breathing, or the inability to be awakened. Pravastatin therapy must be discontinued or temporarily withheld in any patient experiencing an acute or serious condition predisposing to the development of rhabdomyolysis, such as major surgery or severe endocrine disorders. Advanced age (ge 65) and renal impairment are documented predisposing factors for these severe outcomes.

Therapeutic Uses of Selectin

Selectin is used to manage high blood lipid levels and is applied in addressing the chronic risk associated with cardiovascular events. Selectin is considered relevant for conditions characterized by systemic imbalance of blood fats.

This includes its use in treating Primary Hypercholesterolemia, Mixed Dyslipidemia, and conditions like Heterozygous Familial Hypercholesterolemia in appropriate patient groups. A key therapeutic benefit supports the management of high concentrations of Low-Density Lipoprotein (LDL) cholesterol and triglycerides.


Quick Fact: Support for Cardiovascular Health

Property Description
Primary Risk Managed Elevated LDL Cholesterol
Target Conditions Hypercholesterolemia, Mixed Dyslipidemia, Atherosclerosis
Clinical Scenarios Primary and Secondary Cardiovascular Prevention
Patient Benefit Supports long-term functional stability and risk management

Selectin is relevant when supportive symptom management is appropriate for patients facing high risk related to serious cardiovascular events. It is applied in clinical settings for both primary and secondary prevention. This therapeutic approach may assist with maintaining functional stability. In therapeutic areas involving heightened chronic risk, the medication supports the patient during this process, contributing to easing the overall symptom load.

Regulatory References

  1. National Library of Medicine - MedlinePlus

Eligibility and Restrictions for Use

Official Eligibility Profile for Selectin

Regulatory documents strictly define the populations eligible to use Selectin (Pravastatin) and those for whom use is prohibited, restricted, or unestablished.


Absolute Contraindications

Selectin must not be used in patients with the following conditions, as this is designated as an absolute prohibition in regulatory labeling:

  • Active liver disease or unexplained, persistent elevations of serum transaminases.
  • Women who are pregnant or may become pregnant.
  • Nursing mothers (lactation).
  • Known hypersensitivity to Pravastatin or any component of the medication.

Age-Related Eligibility and Limitations

  • Adults: Use is established for the approved indications.
  • Pediatric Patients: Approved for use in patients 8 years of age and older for specific indications, such as Heterozygous Familial Hypercholesterolemia. Safety and effectiveness are not established in children younger than 8 years.
  • Older Adults: While generally permitted, advanced age (65 years and older) is a documented risk factor that may require conditional use and close monitoring.

Condition-Based Restrictions

Certain clinical states require caution or temporary non-use:

  • Organ Function: Patients with severe renal impairment or a history of heavy alcohol use require conditional use and monitoring, as these are predisposing risk factors for muscle effects.
  • Acute Events: The medicine must be temporarily discontinued if a patient is experiencing acute or serious conditions such such as major surgery, severe trauma, or sepsis.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Selectin (Pravastatin) has a defined interaction profile structured around changes in plasma exposure and additive risk for specific adverse effects. The active ingredient is primarily metabolized through non-CYP pathways, meaning interactions often result from different mechanisms, such as those affecting drug transport.

Interaction-Related Restrictions and Constraints

Co-administration with Gemfibrozil (a fibrate) is generally advised to be avoided due to a documented increase in the risk of severe skeletal muscle effects, including myopathy. The use of systemic Fusidic Acid is also officially prohibited in combination with statins. The use of Selectin with substantial quantities of alcohol is associated with an increased risk of hepatic injury.

Pharmacokinetic and Pharmacodynamic Interactions

Certain immunosuppressants and antibiotics significantly modify Selectin’s exposure. Co-administration with Cyclosporine leads to a substantial increase in Selectin's plasma concentrations, linked to the inhibition of hepatic uptake transporters. The macrolide antibiotic Clarithromycin also increases exposure. For agents that inhibit absorption, such as the bile acid sequestrants Cholestyramine and Colestipol, Selectin must be administered at least one hour before or four hours after the sequestrant. Furthermore, the combination with high-dose Niacin (ge 1 g/day) formally increases the risk of muscle-related adverse events.

Mechanism of Action

The core action of Selectin (Pravastatin) involves modulating internal lipid regulation mechanisms through targeted enzyme inhibition and receptor feedback.


Direct Inhibition of Cholesterol Production

The drug works by selectively binding to and competitively inhibiting the enzyme HMG-CoA reductase in the liver . This interaction blocks the rate-limiting step in the mevalonate pathway, directly reducing the synthesis of cholesterol within the liver cells (hepatocytes). This initial molecular step creates a cholesterol deficit, triggering a systemic regulatory response.


⬆️ Cascade-Driven Enhancement of LDL Clearance

As a direct consequence of the reduced intracellular cholesterol, the reduction in intracellular cholesterol initiates the upregulation of Low-Density Lipoprotein (LDL) receptors on its surface . These highly expressed receptors capture and internalize LDL-C from the circulating blood, leading to its accelerated breakdown. This mechanism promotes the liver's function as a scavenger, and this physiological adjustment results in a reduction of plasma LDL-C levels.


Mechanistic Localization in the Liver

The hydrophilic nature of Pravastatin restricts its distribution, ensuring that the majority of its inhibitory activity is concentrated strategically within the liver. This specificity ensures the mechanism primarily modulates the central hepatic pathway for lipid homeostasis; this characteristic may limit engagement with off-target mechanisms.

Dosage and Administration Information

Selectin is administered orally as a solid tablet and is intended for use as an adjunct to a cholesterol-lowering diet. The medicine is taken once daily. The standard adult regimen typically begins with a dose of 40 mg. The dose may subsequently be adjusted based on laboratory measurements, but only after treatment has been sustained for a minimum of four weeks to allow for maximum effect at the current level. The maximum recommended daily dose for adults is 80 mg.

Administration is flexible regarding meals, as the tablet may be taken with or without food. While it can be taken at any time, administration in the evening may be considered.

Dosing is modified for specific patient groups and co-administered treatments. For patients with severe renal impairment or significant hepatic impairment, a starting dose of 10 mg once daily is specified. Pediatric patients (ages 8 to 13) are typically administered 20 mg once daily, while adolescents (14 to 18 years) are given 40 mg once daily. When Selectin is taken concurrently with bile acid-binding resins, the tablet must be administered either one hour before or at least four hours after the resin to maintain proper absorption. The maximum daily dose is capped at 20 mg if co-administered with Cyclosporine and 40 mg if co-administered with Clarithromycin.

Recent Clinical Evidence

Selectin: Recent Clinical Evidence

Overview of Studies in Type 2 Diabetes

Research has investigated the drug in studies involving participants with Type 2 Diabetes (T2D). Studies examined changes in HbA1c levels, a key measure of average blood sugar control over time. Researchers also assessed changes in fasting plasma glucose levels.

Phase 3 clinical trials evaluated the drug as both a monotherapy and as co-administration therapy alongside metformin. Studies compared the co-administration with metformin versus metformin monotherapy to examine differences in glycemic control.

Secondary Measures and Safety Profile

Studies reported changes in body weight in participants. This observation was explored in relation to outcomes noted with other established T2D treatments. Research evaluated the onset of observed changes in measures of hyperglycemia. Long-term data regarding cardiovascular outcomes were not fully evaluated in these studies.

Studies investigated the drug's use and the tolerability profile in elderly participants. Research also examined the pharmacokinetics in individuals with mild kidney impairment.

Adverse Events

Studies identified contraindications, including a history of serious allergic reactions to any component. The most frequently reported adverse events in trials included headache and nausea. The study results indicated that these events were temporary. Other adverse events reported by researchers included dizziness and diarrhea.

Frequently Asked Questions (FAQ)

Common questions about Selectin (FAQ)

Q: Is there a generic version of Selectin available?

The active ingredient contained in Selectin is Pravastatin. According to official information, Pravastatin is available as a generic medicine in many regions.

Q: Does Selectin interact with alcohol or caffeine?

Official labeling advises patients to limit alcohol intake due to a possible increased risk of liver damage. No specific interaction is typically documented for caffeine. A healthcare professional is the best source to review individual habits and risks.

Q: Are there any known foods or supplements that should be avoided while using Selectin?

Regulatory documents advise limiting alcohol and avoiding high doses of Niacin (a B vitamin supplement). No known interaction with common foods like grapefruit or grapefruit juice is documented in the official labeling. Official patient information states that a healthcare professional should be informed about all concomitant use of supplements.

Q: Is Selectin generally considered safe for older adults?

Advanced age, defined as 65 years and older, is identified in official documents as a predisposing factor for certain muscle-related adverse reactions. The use of this medicine in individuals aged 65 and older is associated with regulatory caution and may involve close monitoring.

Q: Is Selectin safe for individuals with a history of heart problems?

Regulatory information indicates that Selectin is used to help reduce the risk of major cardiovascular events, such as heart attack and stroke. Its primary purpose is to help manage these risks by controlling blood lipid levels in adult patients.

Q: Do children or teenagers have different side effect profiles with Selectin compared to adults?

Yes, the safety profile observed in pediatric patients may differ from that of adults. Regulatory documents report specific adverse reactions in children and adolescents aged 8–18 years, including those related to the endocrine system.

Q: What is the average duration of treatment with Selectin, and what happens if it is taken for a long time?

Official guidance indicates that treatment with this class of medicine is typically intended to be long-term, often for life. The long-term therapy is intended to maintain control over blood lipid levels. For patients on sustained therapy, the labeling advises monitoring of liver enzymes.

Q: Why do doctors recommend continuing Selectin even after symptoms improve?

Official information indicates that cholesterol-lowering treatment is often considered long-term because the condition is chronic. If the medicine is discontinued, cholesterol levels may rise again, which may increase the associated health risks.

Q: Does Selectin have a withdrawal period if someone stops taking it, and what are the main risks associated with stopping Selectin suddenly?

Regulatory-based guidance indicates that typical withdrawal symptoms are not expected if the medicine is discontinued. However, the main risk is that cholesterol levels may rise again. A rise in cholesterol is generally associated with an increased risk of cardiovascular events.

Q: If I accidentally miss a dose of Selectin, what is generally recommended?

Official information advises that if a dose is missed, it can generally be taken as soon as it is remembered. However, specific instructions regarding a missed dose should be clarified with a healthcare professional. The product information states that two doses should not be administered simultaneously.

Q: Is it necessary to take Selectin at the exact same time every day?

The medicine is prescribed to be taken once daily and the dose may be administered at any time of the day, with or without food. Although flexibility exists, taking the dose around the same time daily can help establish and maintain a consistent routine.

Q: Can Selectin be crushed or split for easier use?

Official guidance generally states that the tablets should be swallowed whole. The official guidance states that the tablets should not be crushed, split, or chewed before swallowing.

Q: Does Selectin require regular blood tests while in use?

Official information requires liver enzyme tests before starting therapy and as clinically indicated thereafter. This testing helps monitor liver health. Routine periodic monitoring for all patients is generally no longer required.

Q: What are the most serious, but rare, side effects reported for Selectin?

The official safety profile identifies serious risks including Myopathy (muscle disease), Rhabdomyolysis (severe muscle breakdown), and Fatal or Non-fatal Hepatic Failure (liver failure). Rare post-marketing reports include Immune-Mediated Necrotizing Myopathy (IMNM).

Q: What should be done if someone experiences a severe skin reaction while on Selectin?

Hypersensitivity (severe allergic reaction) is listed as an official contraindication. The official labeling indicates that a healthcare professional should be notified immediately if symptoms of a severe allergic reaction occur, such as a serious skin reaction.

Q: Does Selectin affect sleep patterns?

Regulatory documents list side effects within the nervous system that include reports of sleep disorders and insomnia. Insomnia refers to difficulty falling or staying asleep.

Q: Is fatigue or drowsiness a common side effect of Selectin?

Official labeling describes feelings of malaise (a general feeling of discomfort or illness) and fatigue as possible adverse reactions. These effects are typically reported in post-marketing experience and are not listed among the most frequently reported adverse events in clinical trials.

Q: Can Selectin change a person's appetite?

Adverse events reported in the gastrointestinal system include symptoms such as anorexia, which is described as a loss of appetite.

Q: Can Selectin cause problems with vision?

Regulatory information notes that the medicine may occasionally cause certain visual disturbances. Specifically, reports of blurred or double vision have been documented.

Q: Do regulatory agencies have specific warnings about driving while taking Selectin?

Official information advises patients to use caution when driving or operating machinery until it is known how the medicine affects an individual. This is because it may cause dizziness or visual disturbances.

Q: What does the research say about Selectin's long-term impact on the brain?

Official labeling notes rare post-marketing reports of cognitive impairment associated with this class of medicine. This includes symptoms like memory loss or confusion. These effects are generally described as non-serious and reversible upon discontinuation of treatment.

Q: What is the purpose of the black box warning on Selectin's labeling, if it has one?

Selectin (Pravastatin) does not currently carry a Boxed Warning (often referred to as a Black Box Warning) in its official FDA labeling. This type of warning is reserved for the most serious safety concerns.

Q: Does Selectin carry a risk of dependence or addiction?

The medicine is classified as a lipid-lowering agent and belongs to the statin pharmacological class. Official information confirms that Selectin is not associated with dependence or addiction.

Q: What if I'm already taking herbal supplements; can I use Selectin?

Official labeling states that a healthcare professional should be informed about the use of all concomitant medications, herbal products, or other supplements. This allows for a full review of potential interactions or safety concerns.

Q: Are there specific genetic factors that affect how Selectin works?

While not detailed in the general patient label, clinical research indicates that the risk of certain adverse effects may be genetically determined. For example, some individuals may have a higher genetic predisposition to muscle-related risks like rhabdomyolysis.

How should Selectin be stored and disposed of?

The official requirements for storing Selectin (pravastatin sodium) tablets ensure product stability and safety.

Storage Requirements

Selectin must be stored at controlled room temperature, between 20°C and 25°C (68°F and 77°F). It is mandatory to protect the tablets from moisture and excess heat; therefore, the medicine should be kept in its original container and the container must be kept tightly closed.

Child Safety and Disposal

The medication must always be stored out of the reach and sight of children. For disposal, the preferred method is to use a drug take-back program. If a program is unavailable, unused or expired tablets should be mixed with an undesirable substance, sealed in a bag, and thrown into the household trash. The tablets must not be flushed down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Selectin found in:

A-Z Index: